Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of septic shock in hospitalized patients with hematologic malignancies

• Published in: Cancer biology & therapy Vol. 8; no. 12; pp. 1095 - 1100
• Main Authors: Mato, Anthony, Fuchs, Barry D., F. Heitjan, Daniel, Mick, Rosemarie, Halpern, Scott D., Shah, Payal D., Jacobs, Samantha, Olson, Erin M., Schuster, Stephen J., Ujjani, Chaitra, Chong, Elise A., Loren, Alison W., Miltiades, Andrea N., Luger, Selina
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 15.06.2009
• Subjects: Binding; Biology; Bioscience; Calcium; Cancer; Case-Control Studies; Cell; Cohort Studies; Cycle; Female; Hematologic Neoplasms - complications; Humans; Landes; Male; Middle Aged; Multivariate Analysis; Organogenesis; Proteins; ROC Curve; Shock, Septic - blood; Shock, Septic - diagnosis; Shock, Septic - prevention & control; Systemic Inflammatory Response Syndrome - diagnosis
• ISSN: 1538-4047; 1555-8576; 1555-8576
• DOI: 10.4161/cbt.8.12.8528

Background: The systemic inflammatory response syndrome (SIRS) criteria have not been validated in patients with hematologic malignancies (HM). Objective: To determine whether daily assessment of SIRS criteria allows early identification of HM patients who will develop septic shock (SS). Design: Observational, single-center, nested case-control study. Setting: Oncology unit of a tertiary care center. Patients: 547 consecutive, hospitalized, HM subject were enrolled. Using incidence-density sampling, 184 controls were matched to 46 SS cases. Measurements: The study exposure was the SIRS score. The study outcome was the development of SS during the hospitalization. Main Results: 8.4% of subjects developed SS. SIRS scores measured 24 hours prior to SS were significantly higher in cases than in controls (2.1 vs. 1.4, p